Literature DB >> 7893135

Germline p53 mutations and heritable cancer.

D Malkin1.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7893135     DOI： 10.1146/annurev.ge.28.120194.002303

Source DB:  PubMed          Journal:  Annu Rev Genet        ISSN： 0066-4197            Impact factor:   16.830


× No keyword cloud information.
  13 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

Review 2.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

3.  Dominant-negative p53 mutations selected in yeast hit cancer hot spots.

Authors:  R K Brachmann; M Vidal; J D Boeke
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

4.  FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.

Authors:  Hanjun Li; Xiuguo Han; Shengbing Yang; Yongjie Wang; Yang Dong; Tingting Tang
Journal:  Oncogene       Date:  2021-03-14       Impact factor: 9.867

Review 5.  Genetic susceptibility to breast cancer.

Authors:  Nasim Mavaddat; Antonis C Antoniou; Douglas F Easton; Montserrat Garcia-Closas
Journal:  Mol Oncol       Date:  2010-05-21       Impact factor: 6.603

Review 6.  Understanding breast cancer risk -- where do we stand in 2005?

Authors:  R G Dumitrescu; I Cotarla
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

7.  Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation.

Authors:  S Venkatachalam; Y P Shi; S N Jones; H Vogel; A Bradley; D Pinkel; L A Donehower
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

8.  Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.

Authors:  L Cheng; Z Zhou; A Flesken-Nikitin; I A Toshkov; W Wang; J Camps; T Ried; A Y Nikitin
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

9.  Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.

Authors:  Karita Peltonen; Laureen Colis; Hester Liu; Sari Jäämaa; Henna M Moore; Juulia Enbäck; Pirjo Laakkonen; Anne Vaahtokari; Richard J Jones; Taija M af Hällström; Marikki Laiho
Journal:  PLoS One       Date:  2010-09-27       Impact factor: 3.240

Review 10.  Biology of urothelial tumorigenesis: insights from genetically engineered mice.

Authors:  Xue-Ru Wu
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.